Yuichiro Amano

1.3k total citations · 1 hit paper
31 papers, 820 citations indexed

About

Yuichiro Amano is a scholar working on Molecular Biology, Surgery and Epidemiology. According to data from OpenAlex, Yuichiro Amano has authored 31 papers receiving a total of 820 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Surgery and 10 papers in Epidemiology. Recurrent topics in Yuichiro Amano's work include Cholesterol and Lipid Metabolism (6 papers), Liver Disease Diagnosis and Treatment (6 papers) and Lipoproteins and Cardiovascular Health (5 papers). Yuichiro Amano is often cited by papers focused on Cholesterol and Lipid Metabolism (6 papers), Liver Disease Diagnosis and Treatment (6 papers) and Lipoproteins and Cardiovascular Health (5 papers). Yuichiro Amano collaborates with scholars based in Japan. Yuichiro Amano's co-authors include Ryuichi Tozawa, Tomoyuki Nishimoto, Yoshimi Imura, Yasuo Sugiyama, Yukimasa Makita, Takatoshi Kiba, Yoshinori Tajima, Takafumi Yamashino, Aya Imamura and Takeshi Mizuno and has published in prestigious journals such as Nature Communications, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Yuichiro Amano

30 papers receiving 797 citations

Hit Papers

Low immunogenicity of LNP allows repeated administrations... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
    2021 209 citations Eriya Kenjo, Hiroyuki Hozumi et al. Nature Communications profile →

Peers

Yuichiro Amano
Bridget S. Gosis United States
Lei Lv China
William McDowell Germany
Wei Cai China
Rachel Avner Israel
Yunbae Pak South Korea
Lyn M. Powell United Kingdom
Tomofumi Fujino Japan
Bridget S. Gosis United States
Yuichiro Amano
Citations per year, relative to Yuichiro Amano Yuichiro Amano (= 1×) peers Bridget S. Gosis

Countries citing papers authored by Yuichiro Amano

Since Specialization
Citations

This map shows the geographic impact of Yuichiro Amano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichiro Amano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichiro Amano more than expected).

Fields of papers citing papers by Yuichiro Amano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichiro Amano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichiro Amano. The network helps show where Yuichiro Amano may publish in the future.

Co-authorship network of co-authors of Yuichiro Amano

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichiro Amano. A scholar is included among the top collaborators of Yuichiro Amano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichiro Amano. Yuichiro Amano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kenjo, Eriya, Hiroyuki Hozumi, Yukimasa Makita, et al.. (2021). Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nature Communications. 12(1). 7101–7101. 209 indexed citations breakdown →
2.
Amano, Yuichiro, Mayumi Imai, Kimio Tohyama, et al.. (2018). Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochemical and Biophysical Research Communications. 497(1). 207–213. 8 indexed citations
3.
Muraki, Yo, et al.. (2017). Elevation of liver endoplasmic reticulum stress in a modified choline-deficient l -amino acid-defined diet-fed non-alcoholic steatohepatitis mouse model. Biochemical and Biophysical Research Communications. 486(3). 632–638. 8 indexed citations
4.
Teranishi, Hitoshi, Masafumi Hayashi, Kenji Mori, et al.. (2017). Role of neuromedin U in accelerating of non-alcoholic steatohepatitis in mice. Peptides. 99. 134–141. 9 indexed citations
5.
Morimoto, Megumi, Yuichiro Amano, Masahiro Oka, et al.. (2017). Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f. PLoS ONE. 12(12). e0189480–e0189480. 16 indexed citations
6.
7.
Amano, Yuichiro, et al.. (2017). Farnesoid X receptor antagonist exacerbates dyslipidemia in mice. Pharmacological Reports. 70(1). 172–177. 5 indexed citations
8.
Yoshimura, Yukihiro, et al.. (2016). Diseases affecting patients returning from abroad: Experience of a travel clinic in Japan from 2004 to 2014. Journal of Infection and Chemotherapy. 23(1). 35–39. 2 indexed citations
9.
10.
Yoshimura, Yukihiro, et al.. (2015). Cavity Forming Pneumonia Due to Staphylococcus aureus Following Dengue Fever. American Journal of Tropical Medicine and Hygiene. 93(5). 1055–1057. 9 indexed citations
11.
Yoshimura, Yukihiro, et al.. (2015). Round Pneumonia with Murine Typhus after Travel to Indonesia. Journal of Travel Medicine. 22(5). 353–354. 5 indexed citations
12.
13.
Amano, Yuichiro, et al.. (2014). Antidyslipidemic effects of a farnesoid X receptor antagonist in primates. Life Sciences. 106(1-2). 25–31. 11 indexed citations
14.
Amano, Yuichiro, et al.. (2013). Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates. European Journal of Pharmacology. 723. 108–115. 15 indexed citations
15.
Shiomi, Masashi, Satoshi Yamada, Yuichiro Amano, Tomoyuki Nishimoto, & Takashi Ito. (2008). Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid‐rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. British Journal of Pharmacology. 154(5). 949–957. 24 indexed citations
16.
Tajima, Yoshinori, Aya Imamura, Takatoshi Kiba, et al.. (2004). Comparative Studies on the Type-B Response Regulators Revealing their Distinctive Properties in the His-to-Asp Phosphorelay Signal Transduction of Arabidopsis thaliana. Plant and Cell Physiology. 45(1). 28–39. 114 indexed citations
17.
Amano, Yuichiro, et al.. (2003). Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. European Journal of Pharmacology. 466(1-2). 155–161. 36 indexed citations
18.
Nishimoto, Tomoyuki, Ryuichi Tozawa, Yuichiro Amano, et al.. (2003). Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochemical Pharmacology. 66(11). 2133–2139. 64 indexed citations
19.
Nishimoto, Tomoyuki, Yuichiro Amano, Ryuichi Tozawa, et al.. (2003). Lipid‐lowering properties of TAK‐475, a squalene synthase inhibitor, in vivo and in vitro. British Journal of Pharmacology. 139(5). 911–918. 59 indexed citations
20.
Kawaguchi, Takeshi, Yukio Hoshino, Fahad Imtiaz Rahman, et al.. (1996). FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A.. PubMed. 28(2). 1062–3. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bridget S. Gosis Breakdown of academic impact, for papers by Lei Lv Breakdown of academic impact, for papers by William McDowell Breakdown of academic impact, for papers by Wei Cai Breakdown of academic impact, for papers by Rachel Avner Breakdown of academic impact, for papers by Yunbae Pak Breakdown of academic impact, for papers by Lyn M. Powell Breakdown of academic impact, for papers by Tomofumi Fujino
Rankless by CCL
2026